WESTMINSTER, Colo.--(BUSINESS WIRE)--
TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference.Management will participate in one-on-one meetings on Monday, September 14 and Tuesday, September 15, and will participate in a Fireside chat on Monday, September 14 at 5:00 p.m. ET.
A webcast replay of the Fireside chat will be available for 90 days following the Fireside chat in the Events section of the TriSalus Investor website at www.investors.trisaluslifesci.com.
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to treat the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development. In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.
A toll-like receptor 9 (TLR9) agonist is a type of drug that activates TLR9, a sensor on certain immune cells that recognizes specific DNA patterns and turns on an immune response. Think of it like pressing a doorbell that wakes up parts of the immune system; in drug development this approach is used to boost vaccines or cancer immunotherapies, so progress in trials, safety data, or approvals can materially affect a biotech company's prospects and valuation.
hepatic arterial infusionmedical
Hepatic arterial infusion is a medical procedure that delivers medicines directly into the artery that supplies blood to the liver, allowing higher drug concentrations to reach liver tumors while limiting exposure to the rest of the body. For investors, it matters because the technique influences clinical trial design, potential market size, manufacturing and device demand, and revenue prospects for drugs or catheter systems tied to liver-directed therapies—think of it as using a garden hose to water only one plant instead of sprinkling the whole yard.
phase 1 clinical trialsmedical
Phase 1 clinical trials are the first tests of a new drug or medical treatment in humans, done with a small number of volunteers to check safety, side effects, and how the body handles the treatment (such as dosing). For investors, phase 1 is an early de‑risking milestone: successful results let a program advance to larger trials and reduce uncertainty, while safety problems or poor dosing results can sharply affect a drug’s value and development timeline — think of it as the first road test of a prototype.
fda-cleared devicesregulatory
Medical devices that the U.S. Food and Drug Administration has reviewed and authorized for marketing through its 510(k) clearance pathway by finding them substantially equivalent to a legally marketed predicate device; this clearance allows the device to be sold in the U.S. but is different from the FDA’s premarket approval process for higher‑risk devices. Investors track clearance because it is a key regulatory milestone that enables sales, reduces regulatory uncertainty, and affects commercial and reimbursement prospects—like a driver’s license letting a product legally operate on public roads.
